{"id":54809,"date":"2023-03-14T13:06:25","date_gmt":"2023-03-14T12:06:25","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/eureka-therapeutics-licenses-promising-antibody-targeting-mesothelin-from-the-national-cancer-institute\/"},"modified":"2023-03-14T13:06:25","modified_gmt":"2023-03-14T12:06:25","slug":"eureka-therapeutics-licenses-promising-antibody-targeting-mesothelin-from-the-national-cancer-institute","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/eureka-therapeutics-licenses-promising-antibody-targeting-mesothelin-from-the-national-cancer-institute\/","title":{"rendered":"Eureka Therapeutics Licenses Promising Antibody Targeting Mesothelin from the National Cancer Institute"},"content":{"rendered":"
\n

EMERYVILLE, Calif.–(BUSINESS WIRE)–Eureka Therapeutics, Inc., a clinical-stage biotechnology company developing novel T-cell therapies to treat cancer, today announced it has entered into a license agreement with the National Cancer Institute (NCI), part of the National Institutes of Health, to develop and commercialize a novel antibody targeting mesothelin (MSLN) in combination with Eureka\u2019s proprietary ARTEMIS\u00ae<\/sup> T-cell receptor platform.\n<\/p>\n

<\/a><\/p>\n

\nMSLN is a cell-surface protein overexpressed in many solid tumors, including mesothelioma, ovarian, pancreatic, breast and lung cancers, making it a promising target for cancer therapies. The NCI antibody licensed to Eureka has shown potential in preclinical studies to selectively bind to and kill cancer cells expressing MSLN while sparing normal cells, which could make it an effective cancer treatment.\n<\/p>\n

\nEureka has previously demonstrated that its proprietary ARTEMIS T-cell receptor platform has several advantages over conventional chimeric antigen receptors (CARs), including better tumor infiltration, safety, and T cell persistence. By combining the newly licensed MSLN-targeting antibody with the ARTEMIS T-cell receptor platform, Eureka and NCI intend to develop a next-generation T-cell therapy that can effectively target and eliminate MSLN-expressing cancer cells.\n<\/p>\n

\n\u201cWe are excited to add this promising antibody to our ARTEMIS receptor portfolio and to advance the development of a potentially transformative T-cell therapy for solid tumors,\u201d said Dr. Cheng Liu, President and CEO of Eureka Therapeutics. \u201cOur goal is to develop safe and effective T-cell therapies to treat MSLN-expressing cancers. We believe the combination of our ARTEMIS platform and this novel antibody targeting MSLN is a promising approach to achieve this goal.\u201d\n<\/p>\n

\n\u201cThe license of NCI\u2019s MSLN-targeting antibody highlights our commitment to advancing promising cancer therapies,\u201d said Dr. Ira Pastan, Chief Emeritus of the Laboratory of Molecular Biology and Head of the Molecular Biology Section at the NCI Center for Cancer Research. \u201cSuch partnerships have the potential to bring transformative therapies to patients.\u201d\n<\/p>\n

\nEureka plans to continue preclinical development of the antibody to support an investigational new drug (IND) application with the US Food and Drug Administration (FDA).\n<\/p>\n

\nABOUT EUREKA THERAPEUTICS, INC.<\/b>\n<\/p>\n

\nEureka Therapeutics, Inc. is a privately held clinical-stage biotechnology company focused on developing novel T-cell therapies to treat cancers. Its core technology centers around its proprietary ARTEMIS\u00ae cell receptor platform<\/a> and E-ALPHA\u00ae antibody discovery platform for the discovery and development of potentially safer and more effective T-cell therapies for the treatment of solid tumors and hematologic malignancies. The company currently has two clinical programs, ET140203 (ARYA1<\/a> for adults and ARYA2<\/a> for pediatrics) and ECT204 (ARYA3<\/a>), in Phase I\/II US trials in patients with advanced liver cancer.\n<\/p>\n

\nEureka Therapeutics, Inc. is headquartered in the San Francisco Bay Area. For more information on Eureka, please visit www.eurekatherapeutics.com<\/a>. ARTEMIS and E-ALPHA are registered trademarks owned by Eureka.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nEureka Therapeutics, Inc.
\n
Natalie Liu
\n
Investor Relations
\n
510-318-9215
\n
IR@eurekainc.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

EMERYVILLE, Calif.–(BUSINESS WIRE)–Eureka Therapeutics, Inc., a clinical-stage biotechnology company developing novel T-cell therapies to treat cancer, today announced it has entered into a license agreement with the National Cancer Institute (NCI), part of the National Institutes of Health, to develop and commercialize a novel antibody targeting mesothelin (MSLN) in combination with Eureka\u2019s proprietary ARTEMIS\u00ae T-cell … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-54809","6":"format-standard","7":"category-industry"},"yoast_head":"\nEureka Therapeutics Licenses Promising Antibody Targeting Mesothelin from the National Cancer Institute - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/eureka-therapeutics-licenses-promising-antibody-targeting-mesothelin-from-the-national-cancer-institute\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Eureka Therapeutics Licenses Promising Antibody Targeting Mesothelin from the National Cancer Institute - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"EMERYVILLE, Calif.–(BUSINESS WIRE)–Eureka Therapeutics, Inc., a clinical-stage biotechnology company developing novel T-cell therapies to treat cancer, today announced it has entered into a license agreement with the National Cancer Institute (NCI), part of the National Institutes of Health, to develop and commercialize a novel antibody targeting mesothelin (MSLN) in combination with Eureka\u2019s proprietary ARTEMIS\u00ae T-cell ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/eureka-therapeutics-licenses-promising-antibody-targeting-mesothelin-from-the-national-cancer-institute\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-03-14T12:06:25+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230314005352\/en\/774526\/21\/Eureka_logo_med.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/eureka-therapeutics-licenses-promising-antibody-targeting-mesothelin-from-the-national-cancer-institute\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/eureka-therapeutics-licenses-promising-antibody-targeting-mesothelin-from-the-national-cancer-institute\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Eureka Therapeutics Licenses Promising Antibody Targeting Mesothelin from the National Cancer Institute\",\"datePublished\":\"2023-03-14T12:06:25+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/eureka-therapeutics-licenses-promising-antibody-targeting-mesothelin-from-the-national-cancer-institute\\\/\"},\"wordCount\":478,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/eureka-therapeutics-licenses-promising-antibody-targeting-mesothelin-from-the-national-cancer-institute\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230314005352\\\/en\\\/774526\\\/21\\\/Eureka_logo_med.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/eureka-therapeutics-licenses-promising-antibody-targeting-mesothelin-from-the-national-cancer-institute\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/eureka-therapeutics-licenses-promising-antibody-targeting-mesothelin-from-the-national-cancer-institute\\\/\",\"name\":\"Eureka Therapeutics Licenses Promising Antibody Targeting Mesothelin from the National Cancer Institute - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/eureka-therapeutics-licenses-promising-antibody-targeting-mesothelin-from-the-national-cancer-institute\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/eureka-therapeutics-licenses-promising-antibody-targeting-mesothelin-from-the-national-cancer-institute\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230314005352\\\/en\\\/774526\\\/21\\\/Eureka_logo_med.jpg\",\"datePublished\":\"2023-03-14T12:06:25+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/eureka-therapeutics-licenses-promising-antibody-targeting-mesothelin-from-the-national-cancer-institute\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/eureka-therapeutics-licenses-promising-antibody-targeting-mesothelin-from-the-national-cancer-institute\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/eureka-therapeutics-licenses-promising-antibody-targeting-mesothelin-from-the-national-cancer-institute\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230314005352\\\/en\\\/774526\\\/21\\\/Eureka_logo_med.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230314005352\\\/en\\\/774526\\\/21\\\/Eureka_logo_med.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/eureka-therapeutics-licenses-promising-antibody-targeting-mesothelin-from-the-national-cancer-institute\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Eureka Therapeutics Licenses Promising Antibody Targeting Mesothelin from the National Cancer Institute\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Eureka Therapeutics Licenses Promising Antibody Targeting Mesothelin from the National Cancer Institute - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/eureka-therapeutics-licenses-promising-antibody-targeting-mesothelin-from-the-national-cancer-institute\/","og_locale":"en_US","og_type":"article","og_title":"Eureka Therapeutics Licenses Promising Antibody Targeting Mesothelin from the National Cancer Institute - Pharma Trend","og_description":"EMERYVILLE, Calif.–(BUSINESS WIRE)–Eureka Therapeutics, Inc., a clinical-stage biotechnology company developing novel T-cell therapies to treat cancer, today announced it has entered into a license agreement with the National Cancer Institute (NCI), part of the National Institutes of Health, to develop and commercialize a novel antibody targeting mesothelin (MSLN) in combination with Eureka\u2019s proprietary ARTEMIS\u00ae T-cell ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/eureka-therapeutics-licenses-promising-antibody-targeting-mesothelin-from-the-national-cancer-institute\/","og_site_name":"Pharma Trend","article_published_time":"2023-03-14T12:06:25+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230314005352\/en\/774526\/21\/Eureka_logo_med.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/eureka-therapeutics-licenses-promising-antibody-targeting-mesothelin-from-the-national-cancer-institute\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/eureka-therapeutics-licenses-promising-antibody-targeting-mesothelin-from-the-national-cancer-institute\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Eureka Therapeutics Licenses Promising Antibody Targeting Mesothelin from the National Cancer Institute","datePublished":"2023-03-14T12:06:25+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/eureka-therapeutics-licenses-promising-antibody-targeting-mesothelin-from-the-national-cancer-institute\/"},"wordCount":478,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/eureka-therapeutics-licenses-promising-antibody-targeting-mesothelin-from-the-national-cancer-institute\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230314005352\/en\/774526\/21\/Eureka_logo_med.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/eureka-therapeutics-licenses-promising-antibody-targeting-mesothelin-from-the-national-cancer-institute\/","url":"https:\/\/pharma-trend.com\/en\/eureka-therapeutics-licenses-promising-antibody-targeting-mesothelin-from-the-national-cancer-institute\/","name":"Eureka Therapeutics Licenses Promising Antibody Targeting Mesothelin from the National Cancer Institute - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/eureka-therapeutics-licenses-promising-antibody-targeting-mesothelin-from-the-national-cancer-institute\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/eureka-therapeutics-licenses-promising-antibody-targeting-mesothelin-from-the-national-cancer-institute\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230314005352\/en\/774526\/21\/Eureka_logo_med.jpg","datePublished":"2023-03-14T12:06:25+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/eureka-therapeutics-licenses-promising-antibody-targeting-mesothelin-from-the-national-cancer-institute\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/eureka-therapeutics-licenses-promising-antibody-targeting-mesothelin-from-the-national-cancer-institute\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/eureka-therapeutics-licenses-promising-antibody-targeting-mesothelin-from-the-national-cancer-institute\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230314005352\/en\/774526\/21\/Eureka_logo_med.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230314005352\/en\/774526\/21\/Eureka_logo_med.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/eureka-therapeutics-licenses-promising-antibody-targeting-mesothelin-from-the-national-cancer-institute\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Eureka Therapeutics Licenses Promising Antibody Targeting Mesothelin from the National Cancer Institute"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/54809","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=54809"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/54809\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=54809"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=54809"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=54809"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}